Skip to main content
SpringerLink
Log in

Immundiagnostik und Immuntherapie bei Kopf-Hals-Malignomen

  • Conference paper
Chirurgische Therapie von Kopf-Hals-Karzinomen

  • 46 Accesses

Zusammenfassung

Bereits Paul Ehrlich hat zu Beginn dieses Jahrhunderts die Hypothese aufgestellt, daß körpereigene Abwehrstoffe an Krebsabwehrreaktionen beteiligt sind. Diese Hypothese, die später als Immunosurveillance-Theorie von Thomas und Burnet neu definiert wurde, besagt, daß Tumorzellen durch die Expression von Tumor-assoziierten Antigenen vom Immunsystem als „fremd“ erkannt und durch zytotoxische Immunreaktionen aus dem Organismus eliminiert werden [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Boyd W (1966) Spontaneous regression of cancer, 3rd edn. Charles C Thomas, Springfield

    Google Scholar 

  2. Burnet FM (1967) Immunological aspects of malignant diseases. Lancet i: 1171

    Article  Google Scholar 

  3. Takasugi M, Mickey MR, Terasaki PI (1974) Studies on specificity of cell-mediated immunity to human tumors. J Natl Cancer Inst 53: 1527

    PubMed  CAS  Google Scholar 

  4. Herberman RB (1976) Immunologic approaches to the diagnosis of cancer. Cancer 37: 549

    Article  PubMed  CAS  Google Scholar 

  5. Hersh EM, Gutterman JU, Mavligit GM (1976) Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient. Med Clin North Am 60: 623

    PubMed  CAS  Google Scholar 

  6. Davies, DA (1957) What are tumor specific antigens? Nature 254: 653

    Google Scholar 

  7. Abelev GI (1974) a-Fetoprotein as a marker of embryospecific differentiation in normal and tumor tissue. Transpl Res 20: 3

    Google Scholar 

  8. Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122: 467

    Article  PubMed  CAS  Google Scholar 

  9. Thomson DMP, Krupey I, Freedman SO, Gold P (1969) The radioimmunoassay of circulating carcino embryonic antigens of human digestive syst. Proc Natl Acad Sci 64: 161

    Article  PubMed  CAS  Google Scholar 

  10. Terry WD, Henkart PA, Coligan JE, Todd CW (1974) Carcinoembryonic antigen: characterization and clinical applications. Transpl Rev 20: 100

    CAS  Google Scholar 

  11. Hakkinen I, Viikari S (1974) Occurence of fetal sulfoglycoprotein antigen in gastric juice of patients with gastric disease. Ann Surg 169: 277

    Article  Google Scholar 

  12. Hâkkinen IPT (1974) FSA-Foetal Sulphoglycoprotein antigen associated with gastric cancer. Transpl Rev 20: 61

    Google Scholar 

  13. de Thé G, Geser A, Day NE, et al (1978) Epidemiologic evidences for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Uganda prospective study. Nature 274: 756–761

    Article  Google Scholar 

  14. Evans AS, Niederman JC, McCollum RANT (1968) Seroepidemiological studies on infection mononucleosis with EB-virus. N Engl J Med 279: 1121–1127

    Article  PubMed  CAS  Google Scholar 

  15. Merijan TA (1981) Virology and immune mechanisms. Cancer 47: 1091–1094

    Article  Google Scholar 

  16. Herberman RB (1977) Immunogenicity of tumor antigens. Biochem Biophys Acta 473: 93

    PubMed  CAS  Google Scholar 

  17. Wolf A, Micksche M, Bauer H (1981) An improved antigen marker of human lung carcinoma and its use in radioimmunoassay. Br J Cancer 43: 267–275

    Article  PubMed  CAS  Google Scholar 

  18. Winters WD (1979) Humoral response to tumor-associated antigen-melanomas. In: Herberman RB, McIntire KR(eds) Immuno-diagnosis of cancer, part 2. M Dekker, New York Basel, p 825

    Google Scholar 

  19. Köhler G, Howe SC, Milstein C (1976) Fusion between immuno-globulin-secreting and non-secreting myeloma cell lines. EurJ Immunol 6: 292–295

    Article  Google Scholar 

  20. Mitchell MS, Oettgen HF (eds) (1982)Hybridomas in cancer diagnosis and therapy. Prog Cancer Res Ther 21: 1–264

    Google Scholar 

  21. Holmgren J (ed) (1985) Tumor marker antigens. Chartwell Bratt Ltd, pp 1–145

    Google Scholar 

  22. Bast RJJr, Feeny M, Lazarus H, Nadler LM, Colvin RB, Krapp RB (1981) Reactivity of a monoclonal antibody with numan ovarian carcinoma. J Clin Invest 68: 1331–1378

    Article  PubMed  Google Scholar 

  23. Bast RC, Knapp RC (1986) Antigenic marker for ovarian carcinoma. In: Rose NR, Friedman, H, FaheyJL (eds) Manual of clinical laboratory. Am Soc Microbiol, Washington, pp 817–821

    Google Scholar 

  24. Herberman RB, Hollinshead AC, Alford TC, McCoy I, Halterman RH, Leventhal BG (1973) Delayed cutaneous hypersensitivity reactions to extracts of human tumors. Natl Cancer Inst Monogr 37: 189

    PubMed  CAS  Google Scholar 

  25. Hollinshead AC, Jaffurs WR, Alpert LK, Harris JE, Herberman RB (1974) Isolation and identification of soluble skinreactive membrane antigens of malignant and normal human breast cells. Cancer Res 34: 296

    Google Scholar 

  26. Kokoschka EM, Cerni C, Micksche M (1978) Active specific immunotherapy for stage II malignant melanoma. In: Rainer H (ed) Immunotherapy of malignant diseases. Schattauer, Stuttgart New York, pp 308–313

    Google Scholar 

  27. Micksche M, Cerni C, Fischer P, Vetterlein M (1979) Tumor-associated antigens on somatic cell hybrids derived from human lung cancer cells. In: Flath HD, Herfarth Ch, Betzler M (eds) Immunodiagnosis and immunotherapy of malignant tumors — relevance to surgery. Springer, Berlin Heidelberg New York, pp 91–92

    Chapter  Google Scholar 

  28. Catalona WJ, Ratliff TL, McCool RE (1979) Discordance among cell mediated cytolytic mechanisms in cancer patients: importance of assay system. J Immunol 122: 1009

    PubMed  CAS  Google Scholar 

  29. Vose BM, Gallagher P, Moore M, Schofield PF (1981) Specific and non-specific lymphocyte cytotoxicity in colon carcinoma. Br J Cancer 44: 846–855

    Article  PubMed  CAS  Google Scholar 

  30. Herberman RB (ed) (1982) NK cells and other natural effector cells. Academic Press, New York

    Google Scholar 

  31. McCoy JL, Jerome LF, Dean JH, Cannon GB, Doering T, Herberman RB (1974) Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human breast carcinoma. J Natl Cancer Inst 53: 11

    PubMed  CAS  Google Scholar 

  32. McCoy JL (1979) Clinical applications of assays of leukocyte migration inhibition. In: Herberman RB, McIntire KR (eds) Immunodiagnosis of cancer, part 2. M Dekker, New York Basel, p 979

    Google Scholar 

  33. Halliday WJ, Miller S (1972) Leukocyte adherence inhibition: simple test for cell mediated tumour immunity and serum blocking factors. Int J Cancer 9: 477

    Article  PubMed  CAS  Google Scholar 

  34. Vanky FT, Stjernsward I (1979) Lymphocyte stimulation (by autologous tumour biopsy cells). In: Herberman RB, McIntire KR (eds) Immunodiagnosis of cancer, part 2. M Dekker, New York Basel, p 998

    Google Scholar 

  35. Byfield JE, Weintraub I, Klisak I, Lagasse LD (1973) Inhibition of colony formation by cytotoxic antibodies in cervical epidermoid carcinoma. Radiology 107: 685

    PubMed  CAS  Google Scholar 

  36. Dent PB, Liao SK,, McCulloch PB, Stone BR, Singal DB (1982) Absence of melanoma specificity in the reactivity of melanoma patient’s sera with cultured allogeneic melanoma cell lines. Cancer 49: 2043–2048

    CAS  Google Scholar 

  37. Eibler FR, Morton DL (1970) Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25: 362

    Article  Google Scholar 

  38. Penn I (1981) Depressed immunity and the development of cancer. Clin Exp Immunol 46: 459–474

    PubMed  CAS  Google Scholar 

  39. Micksche M, Luger TA (1983) Tumorimmunologie. In: Luger A, Gschnait F (Hrsg) Dermatologische Onkologie. Urban und Schwarzenberg, Stuttgart, S 22–35

    Google Scholar 

  40. Nemoto T (1974) Cell-mediated immune status of breast cancer patients: evaluation by skin tests. J Natl Cancer Inst 53: 641

    PubMed  CAS  Google Scholar 

  41. Micksche M, Luger TA, Michalica W, Tatra G (1978) Investigations of general immune reactivity in untreated cervical carcinoma patients. Oncology 35: 206–209

    Article  PubMed  CAS  Google Scholar 

  42. Micksche M (1980) Immunologische Aspekte des Lungenkarzinoms. In: Denck H (Hrsg) Lungenkarzinom. Holzhausen, Wien, S 255–283

    Google Scholar 

  43. Chakravorty RC, Curutchet HP, Coppolla FS, Park CM, Blaylock WK, Lawrence W (1973) The delayed hypersensitivity reaction in the cancer patient: observations on sensitization by DNCB. Surgery 73: 730

    PubMed  CAS  Google Scholar 

  44. Cunningham TJ, Daut D, Wolfgang PE, Mellyn M, Maciolek S, Sponzo RW, Horton J (1976) A correlation or DNCB-induced delayed cutaneous hypersensitivity reactions and the course of disease in patients with recurrent breast cancer. Cancer 4: 1696

    Article  Google Scholar 

  45. Keller SE, loachim HL, Pearse T, Siletti DM (1976) Decreased T-lymphocytes in patients with mammary cancer. Am J Clin Pathol 65: 445

    PubMed  CAS  Google Scholar 

  46. Bolton PM, Teasdale C, Mander AM, James SL, Davidson JM, Whitehead RH, Newcombe RG, Hughes LE (1976) Immune competence in breast cancer — Relationship of pretreatment. Immunologic test to diagnosis and tumor stage. Cancer Immunol Immunother 1: 251

    Article  Google Scholar 

  47. Micksche M, Colot M, Kucera H (1981) Radioimmunotherapy in advanced cervical cancer. In: Serrou B, Rosenfeld C (eds) Immunopharmacological effects of radiation therapy. EORTC Monogr 8: 499–518

    Google Scholar 

  48. Micksche M (1978) Immunologie und Immunotherapie des Lungenkarzinoms. Experimentelle und klinische Untersuchungen. Wien Klin Wochenschr 90 [Suppl]: 1–28

    CAS  Google Scholar 

  49. Westermann J, Pabst R (1990) Lymphocyte subsets in the blood: a diagnostic window. Immunol Today 11: 406–410

    Article  PubMed  CAS  Google Scholar 

  50. Herberman RB (ed) (1980) Natural cell-mediated immunity against tumors. Academic Press, New York

    Google Scholar 

  51. Lotzova E, McCredie KB (1978) Natural killer cells in mice and man and their biological significance. Cancer Immuno Immunother 215–221

    Google Scholar 

  52. Antonelli P, Stewart W II, Dupont B (1981) Distribution of natural killer cell activity in peripheral blood, cord blood, thymus, lymph nodes and spleen, and the effect of in vitro treatment with interferon preparations. Clin Immunol Immunopathol 19: 168–172

    Article  Google Scholar 

  53. Gorelik E, Wilhout RH, Okumura K, Hobu, S, Herberman, B (1982) Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30: 107–112

    Article  PubMed  CAS  Google Scholar 

  54. Uchida, A, Micksche, M (1981) Suppressor cells for natural killer cell activity in carcinomatous pleural effusions of cancer patients. Cancer Immunol Immunother 11: 255–263

    Google Scholar 

  55. Uchida A, Kolb R, Micksche M (1982) Generation of suppressor cells for natural killer cell activity in cancer patients after surgery. J Natl Cancer Inst 68: 735–741

    PubMed  CAS  Google Scholar 

  56. Uchida A, Colot M, Micksche M (1984) Suppression of natural killer cell activity by adherent effusion cells of cancer patients: suppression of motility, binding capacity and lethal hit of NK cells. Br J Cancer 49: 17–23

    Article  PubMed  CAS  Google Scholar 

  57. Micksche M, Vinzenz K, Kokoschka EM, Kokoschka R (1985) Natural killer cell activity in tumor-drainig lymph nodes: investigations in patients with malignant melanoma and head and neck cancer. Natl Immunol Cell Growth Regul 4: 315–327

    CAS  Google Scholar 

  58. Gerrard TL, Terz JJ, Kaplan AM (1980) Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients. Int Cancer 26: 585

    Article  CAS  Google Scholar 

  59. Yanagawa E, Uchida A, Kokoschka EM, Micksche M (1984) Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK-432 in melanoma patients. Cancer Immuno Immunother 16: 131–136

    CAS  Google Scholar 

  60. JettJR, Mantovani A, Herberman RB (1980) Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol 54: 425–429

    Article  Google Scholar 

  61. Burnet FM (1967) Immunological aspects of malignant diseases. Lancet 1: 1171

    Article  PubMed  CAS  Google Scholar 

  62. Herberman RB (ed) (1980) Natural cell-mediated immunity against tumors. Academic Press, New York

    Google Scholar 

  63. Klein G (1980) Immune and non-immune control of neoplastic development: contrasting effects of host and tumor evolution. Cancer 45: 2486–2499

    Article  PubMed  CAS  Google Scholar 

  64. Mathé G, Schwarzenberg L, Amiel JL (1967) The role of immunology in the treatment of leukaemias and haematosarcomas. Cancer Res 27: 2542–2546

    PubMed  Google Scholar 

  65. Biological response modifiers: Subcommittee Report (ed) NCI Monograph Nr. 63

    Google Scholar 

  66. Meyskens FL Jr (1984) Prevention and treatment of cancer with vitamin A and retinoids. In: Prasad (ed) Vitamins, nutrition and cancer. Karger, Basel, pp 266–273

    Google Scholar 

  67. Morton DL, Eilber FR, Holmes EC, et al (1976) Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol Immunother 1: 93–98

    Article  Google Scholar 

  68. Gutterman JU, Cardenas JO, Blumensein GR, et al (1976) Chemoimmunotherapy for advanced breast cancer: prolongation of remission and survival with BCG. Med J 2: 1222–1225

    Article  CAS  Google Scholar 

  69. Mavligit GM, Gutterman JU, Burgess MA, et al (1975) Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of Duke’s classification. Cancer 36: 2421–2427

    Article  PubMed  CAS  Google Scholar 

  70. McKneally MF, Mayer C, Kausel HW (1976) Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1: 377–381

    Article  PubMed  CAS  Google Scholar 

  71. Holmes EC, Eagan RT (1984) Lung cancer study group: surgical adjuvant therapy of resectable carcinoma of the lung. Proc ASCO Abst C-860: 220

    Google Scholar 

  72. Herr HW, Pinsky CM, Whitmore WF, et al (1983) Effect of intravesical Bacillus Calmette-Guerin ( BCG) on carcinoma in situ of the bladder. Cancer 51: 1323–1326

    Article  PubMed  CAS  Google Scholar 

  73. Kokoschka EM, Micksche M, Luger T (1978) Immunochemotherapie bei Patienten mit disseminiert metastasierendem Melanom Stadium III. Onkologie 1: 98–103

    Article  PubMed  CAS  Google Scholar 

  74. Bast RC, Berek JS, Obrist R, et al (1983) Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum. Cancer Res 3: 1395

    Google Scholar 

  75. Ludwig Lung Cancer Cooperative Group (1978) Clinical experience with the intrapleural administration of corynebacterium. In: Rainer H (ed) Immunotherapy of malignant disease. Schattauer, Stuttgart New York, pp 164–167

    Google Scholar 

  76. Ludwig Lung Cancer Cooperative Group (1982) Intrapleural corynebacterium parvum as adjuvant therapy in operable bronchogenic non-small cell carcinoma: preliminary report. In: Terry WD, Rosenberg SA (eds) Immunotherapy of human cancer. Elsevier, Amsterdam, pp 111–115

    Google Scholar 

  77. Chugai Pharmaceutical Company (1975) Host defense stimulator: antitumor Str. pyogenes preparation: Picibanil (OK-432). Chugai, Tokyo

    Google Scholar 

  78. Okamoto H, Koshimura S, Shoin S, et al (1972) B-hemolytic streptococcus as cancer controller. In: Okamoto H (ed) Chugai Pharmaceutical Company, Tokyo

    Google Scholar 

  79. Micksche M, Klein E (eds) OK432 - a biological response modifier. Ber Postgr Service, Tokyo

    Google Scholar 

  80. Kimura I, Ohnishi T, Yasuhara S, et al (1976) Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer 37: 2201–2203

    Article  PubMed  CAS  Google Scholar 

  81. Micksche M, Kokoschka EM, Sagaster P, et al (1978) Clinical and immunological studies with OK-432 ( Streptococcus pyogenes) on immunotherapy in cancer patients. Onkologie 1: 106–111

    Article  PubMed  CAS  Google Scholar 

  82. Micksche M, Kokoschka EM, Jakesz R, et al (1982) Phase I study of immunotherapy with Streptococcus pyogenes preparation (OK-432). In: Terry W, Rosenberg SA (eds) Immunotherapy of human cancer. Elsevier, New York, pp 443–451

    Google Scholar 

  83. Micksche M, Kokoschka EM, Luger T, et al (1982) Experimental and clinical studies with OK432, a streptococcal preparation with immune modulating properties. In: Serrou B, Rosenfeld C (eds) Human cancer immunology, vol 3. Elsevier Biomedical, New York, pp 31–54

    Google Scholar 

  84. Yanagawa E, Uchida A, Micksche M (1984) Natural cyototoxicity of lymphocytes from lymph nodes draining breast carcinoma and its augmentation by interferon and OK-432. Cancer Immunol Immunother 17: 1–6

    Article  PubMed  CAS  Google Scholar 

  85. Uchida A, Micksche M (1983) Lysis of fresh human tumor cells by autologous blood lymphocytes and pleural effusion lymphocytes activated by OK432. JNCI 71: 673

    PubMed  CAS  Google Scholar 

  86. Uchida A, Micksche M, Hoshino T (1984) Intrapleura1 administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes. Cancer Immunol Immunother 18: 5

    Article  PubMed  CAS  Google Scholar 

  87. Micksche M, Uchida A (1983) Intrapleural adminstration of OK-432 in cancer patients: activation of NK cells and reduction of suppressor cells. Int J Cancer 31: 1–5

    Article  PubMed  Google Scholar 

  88. Vinzenz K, Porteder H, Matejka M, et al (1987) Modulation of NK-activity in regional lymphnodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity. J Cancer Detect Prevent 1: 463–475

    CAS  Google Scholar 

  89. Ishida N (ed) (1986) Immunopotentiating activities of OK-432. Recent advances in the understanding of its mechanism of action. Excerpta Medica, Tokyo

    Google Scholar 

  90. Hoshino T, Uchida A (ed) (1984) Clinical and experimental studies in immunotherapy OK432. Excerpta Medica, Tokyo

    Google Scholar 

  91. Maeda YY, Chihara G (1971) Lentinan, a new immuno-accelerator of cell-mediated responses. Nature 229: 634–635

    Article  PubMed  CAS  Google Scholar 

  92. Chihara G, Taguchi T (1982) Lentinan biological activities and possible clinical use. In: Sigmatan (ed) EOS 3, pp 93–104

    Google Scholar 

  93. Micksche M (1983) Immuntherapie. In: Denck H, Karrer K (Hrsg) Chirurgische Onkologie. Edition Medicine, pp 221–236

    Google Scholar 

  94. Golde DW, Burgaleita C (1978) Glucan activated macrophages: functional properties and cytotoxicity against syngeneic leukemia cells. Prog Cancer Res Ther 7: 201–206

    CAS  Google Scholar 

  95. Mansell PWA, Rowden G (1978) Clinical experiments with the use of glucan. Prog Cancer Res Ther 7: 255–280

    Google Scholar 

  96. Taguchi T (1979) Clinical studies with PSK. Combination therapy of PSK with surgery and chemotherapy research results. Cancer Res 68: 236–240

    Google Scholar 

  97. Experimental on Clinical Studies on Krestin (1978) Investigation Broschüre, pp 1–22

    Google Scholar 

  98. Cmezawo H, Aoyagi T, Suda H, et al (1976) Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes. J Inhib 29: 97–99

    Google Scholar 

  99. Blomgren H, Stronder LE, Easmyr F (1980) Changes in blood lymphocyte population in cancer patients trialed with Bestatin, a new immunomodulator. Biomedicine 32: 178–195

    PubMed  CAS  Google Scholar 

  100. Krown SE, Pinsky CM, Hirshaut Y, et al (1978) Effect of transfer factor in patients with advanced cancer. Br J Med Sci 14: 1026–1038

    CAS  Google Scholar 

  101. Kirchner H (1978) Suppressor cells of immune reactivity in malignancy. Eur J Cancer 14: 453–459

    Article  PubMed  CAS  Google Scholar 

  102. Byron NA, Hobbs RJ (1984) Human lymphocyte studies can predict response to thymic factor therapy. In: Fenichel RL, Chirigas MA (eds) Immunomodulating agents and their mechanisms. M Dekker, New York, pp 565–586

    Google Scholar 

  103. Goldstein AL, Low TLK, Rossio JL, et al (1978) Recent developments in chemistry and biology of thymosin. In: Chirigos MA (ed) Immune modulation and control of neoplasia by adjuvant therapy. Raven Press, New York, pp 281–291

    Google Scholar 

  104. Wara DW, Goldstein A, Doyle NE, et al (1975) Thymosin activity in patients with cellular immune deficiency. N Engl J Med 292: 70–74

    Article  PubMed  CAS  Google Scholar 

  105. Trainin N, Rotter V, Jakir Y, et al (1979) Biochemical and biological properties of THE in animal on human models. Ann NYAcad Sci 332: 9–14

    Article  CAS  Google Scholar 

  106. Goldstein G, Meinaro A (1971) Thymin: a thymic polypeptide causing neuromuscular block of myasthenia gravis. Ann NYAcad Sci 183: 230–240

    Article  CAS  Google Scholar 

  107. Cohen MH, Chrétien DC, Ihde B, et al (1978) Thymosin fraction V prolongs the survival of small cell lung cancer patients treated with intensive combination chemotherapy. Proc Am Assoc Cancer Res 19: 117

    Google Scholar 

  108. Micksche M, Luger Th (1983) Tumorimmunologie. In: Luger A, Gschnait F (Hrsg) Dermatologische Onkologie. Urban and Schwarzenberg, München Wien, S 22–35

    Google Scholar 

  109. Pohl A, Moser K, Micksche M (1981) Human Interferone — Eigenschaften and Möglichkeiten. Wien Klin Wochenschr 93: 439–457

    PubMed  CAS  Google Scholar 

  110. Clemens MJ, McNurlan MA (1985) Regulation of cell proliferation and differentiation by interferons. Biochem J 226: 345–360

    PubMed  CAS  Google Scholar 

  111. Clemens M (1985) Interferons and oncogenes. Nature 313: 531–532

    Article  PubMed  CAS  Google Scholar 

  112. Cantell K (1970) Preparation of human leukocyte interferon. Proc Symp Ser Immunobiol Standard 14: 5–8

    Google Scholar 

  113. Strander H, Cantell K, Carlström G, et al (1973) Clinical and laboratory investigations on man: systemic adminsitration of potent interferon to man. J Natl Cancer Inst 51: 733–742

    PubMed  CAS  Google Scholar 

  114. Gutterman JV, Blumenschein GR, Alexanian A (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93: 399–406

    PubMed  CAS  Google Scholar 

  115. Spiegel RJ (1986) Intro A (Interferon alfa 2b): clinical overview and future directions. Seminars Oncol XIII [Suppl 2]: 89–101

    Google Scholar 

  116. Micksche M, Flener R, Babits R, et al (1985) Recombinant interferon alpha (IFN-alpha 2) for treatment of metastatic melanoma (stage III). In: Ishipami J (ed) Proc 14th Int Congr Chemotherapy: Anticancer Section. Tokyo Press, Toyko, pp 784–785

    Google Scholar 

  117. Ortaldo JR, Pestka S, Slease RB, et al (1980) Augmentation of human NK-cell activity with interferon. Scand J Immunol 126: 1120–1125

    Google Scholar 

  118. Ratain MJ, Golomb HM, Bardawil RG, et al (1987) Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood 69: 872–877

    PubMed  CAS  Google Scholar 

  119. Foon KA, Roth MS, Bunn PA (1986) Alpha interferon treatment of low-grade B-cell Non-Hodgkin’s lymphomas, cutaneous T-Cell lymphomas, and chronic lymphocytic leukemia. Semin Oncol 3 [Suppl 2]: 35–42

    Google Scholar 

  120. Kirkwood JM, Ernstoff M (1986) Potential applications of the interferons in ocology: lessons drawn from studies of human melanoma. Semin Oncol 3 [Suppl 2]: 48–56

    Google Scholar 

  121. Kempf RA, Grunberg SM, Daniels JR, et al (1986) Recombinant interferon alfa-2 (intron A) in a phase II study of renal cell carcinoma. J Biol Resp Modif 5: 27–35

    CAS  Google Scholar 

  122. Abrams DI, Volberding PA (1986) Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. Semin Oncol 3 [Suppl 2]: 43–47

    Google Scholar 

  123. Bonnem EM, Oldham RK (1987) Gamma-interferon: physiology and speculation on its role in medicine. J Biol Resp Modif 6: 275–301

    CAS  Google Scholar 

  124. Old LJ (1985) Tumor necrosis factor. Science 230: 630

    Article  PubMed  CAS  Google Scholar 

  125. Bender B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316: 379–385

    Article  Google Scholar 

  126. Philip R, Epstein LB (1986) Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself–interferon and interleukin 1. Nature 323: 86–89

    Article  PubMed  CAS  Google Scholar 

  127. Pennica D, Hayflick JS, Bringman TS, et al (1985) Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 82: 6060–6064

    Article  PubMed  CAS  Google Scholar 

  128. Murase T, Hotta T, Saito H, et al (1987) Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 69: 467–472

    PubMed  CAS  Google Scholar 

  129. Balkwill FR, Ward BG, Moodie E, et al (1987) Therapeutic potential of tumor necrosis factor–alfa-and gamma-interferon in experimental human ovarian cancer. Cancer Res 47: 4755–4758

    PubMed  CAS  Google Scholar 

  130. Ruscetti F, Mier J, Gootenberg J, et al (1982) The interaction of human Tcell growth factor with normal and neoplastic T cells. In: Mihich E (ed) Biological responses in cancer. Plenum, New York, pp 121–168

    Google Scholar 

  131. Robb JR (1984) Interleukin-2. The molecule and its function. Immunol Today 5: 203–207

    Article  CAS  Google Scholar 

  132. Mule JJ, Shu S, Schwarz S, et al (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science 225: 1487–1489

    Article  PubMed  CAS  Google Scholar 

  133. Rosenberg SA, Lotze MT, Muul LM, et al (1985) Observation on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

    Article  PubMed  CAS  Google Scholar 

  134. Renova G (1978) Modulation of immunity by levamisole. Pharmacol Ther 2: 397–423

    Google Scholar 

  135. Amery WK (1978) A hypothesis: the mechanism of action of levamisole: immune-stora tion through enhanced cell maturation. F Reticuloendoth Soc 20: 187–193

    Google Scholar 

  136. Amery WK, Cosemans J, Goolen HC, et al (1987) Adjuvant therapy with levamisole in resectable lung cancer. Rec Results Cancer Res 68: 168–277

    Google Scholar 

  137. Anthony JM (1982) Yorkshire trial of adjuvant therapy with Levamisole in surgically treated lung cancer. In: Rosenberg SA (ed) Immunotherapy of human cancer. Elsevier, North Holland, pp 35–140

    Google Scholar 

  138. Klefström P (1985) Levamisole in treatment of stage II breast cancer: five year follow up of a randomized double blind study. Cancer 55: 2753–2757

    Article  PubMed  Google Scholar 

  139. Pinsky CM, Wanebo HJ, Elias Y, et al (1982) Randomized trial of levamisole in patients with squamous cell carcinoma of the head and neck. In: Terry W, Rosenberg SA (eds) Immunotherapy of human cancer. Elsevier, North Holland, pp 353–359

    Google Scholar 

  140. Verhagen H, DeCree J, De Cock, et al (1982) Levamisole therapy in patients with colorectal cancer. In: Terry W, Rosenberg SA (eds) Immunotherapy of human cancer. Elsevier, North Holland, pp 225–229

    Google Scholar 

  141. Laurie JA, Moertel CG, Fleming TR, et al (1989) Surgical adjuvant therapy of large bowel cancer: an evaluation of levamisole and fluorouracil. J Clin Oncol 7: 1447–1456

    PubMed  CAS  Google Scholar 

  142. Dresser DW (1968) Adjuvanticity of vitamin A. Nature 217: 527–529

    Article  PubMed  CAS  Google Scholar 

  143. Micksche M, Cerni C, Kokron O, et al (1977) Stimulation of immune response in lung cancer patients by vitamin A therapy. Oncology 34: 234–238

    Article  PubMed  CAS  Google Scholar 

  144. Micksche M, Colot M, Uchida A, et al (1985) Immunomodulation in cancer patients by synthetic biological response modifiers. Cancer Treatm Symp I: 27–35

    Google Scholar 

  145. Hoefer-Janker H, Khazne F, Scheef W (1969) Erste klinische Erfahrungen mit subtoxischen Vitamin-A-Dosen im Rahmen der radiologischen und zytostatischen Tumortherapie. Krebsarzt 4: 203–207

    Google Scholar 

  146. Kokron O, Cerni C, Micksche M, et al (1977) Zur Therapie des inoperablen Bronchuskarzinoms (Ergebnisse einer Pilot-Study). Österr Z Onkol 4/5–6: 106–110

    Google Scholar 

  147. Micksche M (1980) Immunologische Aspekte des Lungenkarzinoms. In: Denk H, Sig-hart W (Hrsg) Das Bronchuskarzinom heute. Holzhausen, Wien, S 255–283

    Google Scholar 

  148. Micksche M, Colot M, Kucera H (1981) Radio-immunotherapy in advanced cervical cancer. In: Dubois JB, Serrou B, Rosenfeld C (eds) Immunopharmacologic effects of radiation therapy. EORTC Monograph Series, vol 8. Raven Press, New York, pp 499–518

    Google Scholar 

  149. Meyskens FL, Alberstd S, Appro MS, et al (1983) Clinical studies of vitamin A and its synthetic derivatives in cancer prevention and treatment. In: Meyskens FL, Prosad KN (eds) Modulation and mediation of cancer by vitamins. Karger, Basel, pp 306–310

    Google Scholar 

  150. Meyskens FL, Gilmartin E, Alberst DJ, et al (1982) Activity of isoretinoin against squamous cell cancer and preneoplastic lesions. Cancer Treatm Resp 66: 1315–1319

    Google Scholar 

  151. Breitman TR, Jelonick SE, Collins SJ (1980) Induction of differentiation of the promyelocytic cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936–2940

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Angewandte und Experimentelle Onkologie, Universität Wien, Wien, Österreich

    M. Micksche

  2. Abteilung für Kiefer- und Gesichtschirurgie, Evangelisches Krankenhaus Wien-Währing, Wien, Österreich

    K. Vinzenz

Authors
  1. M. Micksche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Vinzenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Primarius der Abteilung für Kiefer- und Gesichtschirurgie, Evangelisches Krankenhaus Wien-Währing, Hans-Sachs-Gasse 10-12, A-1180, Wien, Österreich

    Kurt Vinzenz

  2. I. Chirurgische Abteilung, Landeskrankenanstalten Salzburg, Müllner Hauptstraße 48, A-5020, Salzburg, Österreich

    Hans Werner Waclawiczek

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag/Wien

About this paper

Cite this paper

Micksche, M., Vinzenz, K. (1992). Immundiagnostik und Immuntherapie bei Kopf-Hals-Malignomen. In: Vinzenz, K., Waclawiczek, H.W. (eds) Chirurgische Therapie von Kopf-Hals-Karzinomen. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9087-6_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9087-6_26

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82206-7

  • Online ISBN: 978-3-7091-9087-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation